Pharmafile Logo

TechnologyAdvice

- PMLiVE

US FDA launches ultra-rare diseases framework

The draft guidance specifically discusses genome editing and RNA-based therapies

- PMLiVE

N4 Pharma appoints David Solomon as CEO

The company is to be renamed Thalia Therapeutics to reflect its strategic transition

- PMLiVE

Why stigma is a launch risk in rare disease – and what commercial leaders can do about it

Rare disease launches are complex by nature. Yet one of the most consistent risks we see is rarely treated as a launch issue at all: stigma.

Havas Life London

- PMLiVE

New report identifies stigma as a structural barrier in rare disease

The study finds that healthcare settings are a leading source of stigma for people living with rare conditions

- PMLiVE

From Static to Strategic: The 2026 Playbook for Longitudinal Pharma Interaction

Stop pushing content at a burnt-out audience and start creating "Digital Magnetism." Join Impetus Digital to unlock the 2026 Engagement Toolkit—a deep dive into the immersive, longitudinal strategies and newly...

Impetus Digital

- PMLiVE

Novo Nordisk and Vivtex partner in deal worth up to $2.1bn

The companies aim to develop next-generation oral medicines for obesity and diabetes

- PMLiVE

Data, Evidence, Education: Tackling the Global Multi‑Trillion‑Dollar Rare Disease Burden

Rare diseases are individually uncommon, yet together they affect an estimated 300 million+ people worldwide and touch the lives of over one billion when families and caregivers are included. For...

Medscape Education

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links